Philip Vickers, global head of R&D for Shire ($SHPG) Human Genetic Therapies, and group President Sylvie Gregoire touted the fact that their company is investing about 20% of its blockbuster rare-disease drugs business back into R&D. Hours later, Shire HGT announced its acquisition of the small biotech Lotus Tissue Repair for an undisclosed amount to gain a new therapy for a genetic skin disease. The deal went into the win category for Lotus investor Third Rock Ventures.
